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SUMMARY
Background: One of the key gene involved in chronic diffuse liver
diseases pathogenesis, including nonalcoholic fatty liver 
disease are genes encoding the synthesis of glutathione-S-trans-
ferases. The objective of the study was to investigate a possible
link between A313G polymorphism of the GSTP1 gene and 
biochemical blood parameters in nonalcoholic fatty liver disease
patients.
Methods: Gene polymorphism of GSTP1 (A313G) in 64 non-
alcoholic fatty liver disease patients and 20 healthy individuals
(control group) was studied. The range of investigated 
biochemical blood parameters included: total bilirubin and its
fractions, cholesterol, triglycerides, uric acid, total protein and
albumin, urea, creatinine, plasma enzyme activity.
Results: G-allele significantly more frequently by 2.47 times (OR
= 2.47, CI = 1.01-6.03, p<0.05) occurred in observed patients
compared with healthy individuals. Total bilirubin level in blood of
patients with GG-genotype was by 19.7% (p = 0.03) and by
36.9% (p = 0.04) higher compared with AA-genotype and AG-
genotype carriers respectively. Presence of G-allele was associated
with increased alanine aminotransferase activity, which was 
significantly higher in observed patients AG- and GG-genotypes
carriers compared to patients with-AA genotype at 60.7% (p =
0.03) and 51.0% (p = 0.04) respectively. 
Conclusions: Frequency of G-allele of GSTP1 gene was in
2.47 times (OR = 2.47, CI = 1.01-6.03, p<0.05) higher in
nonalcoholic fatty liver disease patients compared with healthy
individuals in Ukrainian population. Presence of G-allele was
associated with increased concentration of total bilirubin and
higher activity of cytolytic syndrome in observed patients.
Abbreviations: CDLD – chronic diffuse liver diseases, NAFLD –
nonalcoholic fatty liver disease, GST – glutathione-S-transferase,
AST – aspartate aminotransferase, ALT – alanine amino-
transferase, LDH – lactate dehydrogenase, GGT – gamma-
glutamyl transferase, AP – alkaline phosphatase 
RÉSUMÉ
Association entre le polymorphisme A313G du gène GSTP1 
et les paramètres biochimiques sanguins chez les patients avec
stèatose hèpatique non alcoolique
L'introduction: L'un des principaux gènes impliqués dans la
pathogenèse des maladies chroniques du foie, y compris la
stéatose non alcoolique hépatique sont des gènes codant la 
synthèse de glutathion-S-transférases. L'objectif de notre étude
est d'enquêter sur un lien possible entre polymorphisme A313G
du gène GSTP1 et les paramètres biochimiques sanguins chez les
patients avec de la possédant la stéatose non alcoolique hépatique.
Matériaux et Méthodes: On a étudié le Polymorphisme du gène de
la GSTP1 (A313G) chez les 64 patients malades de stéatose non
alcoolique hépatique et de 20 individus sains (groupe de contrôle).
La gamme de paramètres biochimiques sanguins concernés inclus:
bilirubine totale et ses fractions, cholestérol, triglycérides, acide
urique, protéines totales et de l'albumine, de l'urée, la créatinine,
l'activité enzymatique du plasma.
Résultats: G-allèle de gène GSTP1 a été observée 2,47 fois plus
fréquemment (OR = 2,47, IC = 1,01-6,03, p <0,05) chez les
patients observés par rapport aux individus sains. Le niveau de
bilirubine total dans le sang des patients de génotype GG-est à
19,7% (p = 0,03) et de 36,9% (p = 0,04) plus élevé par rapport
à un génotype AA-AG-porteuses et génotypiques respectivement.
La présence de G-allèle a été associée à une augmentation de 
l'activité d'alanine aminotransferase, ce qui était significativement
plus élevé chez les patients observés et AG-GG-porteuses géno-
types par rapport aux patients avec le génotype AA à 60,7% (p =
0,03) et 51,0 % (p = 0,04), respectivement.
Conclusions: Fréquence de G-allèle du gène GSTP1 était 2,47
fois (OR = 2,47, IC = 1,01-6,03, p <0,05) plus élevée chez les
patients avec de la stéatose non alcoolique hépatique par 
rapport aux individus sains. Présence de G-allèle a été associée à
une augmentation de concentration de la bilirubine totale et
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INTRODUCTION
O
ne of the key genes involved in chronic 
diffuse liver diseases (CDLD) pathogenesis,
including nonalcoholic fatty liver disease
(NAFLD) are genes encoding the synthesis of glutathione-
S-transferase (GST), – second phase enzyme detoxification
systems that protect from endogenous oxidative stress and
exogenous toxins, by catalysing of glutathione sulfuric groups
conjugation and decontaminating of lipid and DNA oxida-
tion products [8, 10]. The group of GST enzymes consists of
cytosolic, mitochondrial and microsomal fractions. Eight
classes of soluble cytoplasmic enzyme isoforms of GST are
known [3]. In turn, there are three GST genes, each of them
is responsible for the synthesis of different enzyme isoforms
[11]. Single (A to G) substitution at nucleotide position 313
in GSTP1 gene, changing an isoleucine to a valine amino
acid, is present homozygously in 4 to 12% of the population,
causes to the reduced enzymatic GST activity and plays an
important role in different diseases development [5]. K. Wu
et al. investigated that GSTP1 313 G/G polymorphism is a
strong predisposing risk factor for bladder cancer [12]. L. Qin
et al., found that the genes GSTM3 and GSTP1 promoter
methylation, which causes dysfunction of intracellular anti-
oxidant defense system, more often occurs in patients with
acute and chronic liver failure due to hepatitis B virus, 
compared with patients with compensated viral hepatitis.
Determination of methylated promoters of GSTP1 and
GSTM3 genes can serve as a prognostic factor in the 
development of acute and chronic liver failure in these
patients [9]. I.A. Goncharova et al. showed that patients with
liver cirrhosis AA genotype carriers has 2.5 times higher 
survival rate compared with the patients with the GG and
AG genotypes of GSTP1  gene [4]. Despite of intensive 
investigations of the role of GSTP1 gene polymorphism
(A313G) in the pathogenesis of different forms of CDLD, its
association with appearance and severity of NAFLD should
be clarified.
The objective of the study was to investigate a possible
link between A313G polymorphism of the GSTP1 gene and
biochemical blood parameters in NAFLD patients.
MATERIAL AND METHODS
A313G polymorphism of GSTP1 gene was studied in 64
patients with NAFLD and 20 healthy individuals (control
group). Blood samples were obtained in the morning before
taking meal from antecubital vein in the first day of hospi-
talization until the appointment of treatment. 5% solution of
disodium salt of ethylene diamine tetraacetate was used as an
anticoagulant. The study protocol was in accordance with
the revised Helsinki Declaration (2008) and was approved by
the local medical ethics committee. Written informed 
consent was obtained from all the participants.
All of the patients and healthy volunteers underwent 
general complex clinical, laboratory and instrumental diag-
nostic investigations. Biochemical studies were performed on
the blood biochemical analyzer "Accent-200" ("Cormay SA",
Poland). The range of indicators of biochemical blood 
analysis included: total bilirubin and its fractions, cholesterol,
triglycerides, uric acid, total protein and albumin, urea, crea-
tinine, plasma enzyme activity (aspartate aminotransferase
(AST), alanine aminotransferase (ALT), lactate dehydroge-
nase (LDH), gamma-glutamyl transferase (GGT), alkaline
phosphatase (AP)). 
Investigation of A313G polymorphism of GSTP1 gene
was performed in the state institution "Reference Center for
Molecular Diagnostics of the Ministry of Public Health of
Ukraine" (Kyiv, Ukraine). Genomic DNA for molecular
genetic studies was isolated from peripheral blood using com-
mercial test kits "innuPREP Blood DNA Mini Kit" (Analytik
Jena, Germany) using centrifugal filters. To determine the
polymorphic variants of GSTP1 (A313G) rs 1695 modified
protocols of oligonucleotide primers were used [2] using the
method of polymerase chain reaction and subsequent analysis
of restriction fragment length polymorphism. Investigation of
gene domain was amplified using specific primers
(«Metabion», Germany), mentioned in table 1.
The products of amplified DNA fragments of GSTP1
gene underwent hydrolytic cleavage using restriction endonu-
cleases and BstUI Alw261 (BsmAI) («Thermo Scientific»,
USA). Amplified fragments were analyzed by 2% agarose gel,
and restriction fragment GSTP1 (A313G) – 3% agarose gel
(agarose company «Cleaver Scientific», UK), with the 
addition of ethidium bromide, molecular weight marker
GeneRuler 50 bp DNA Ladder («Thermo Scientific», USA)
and subsequent visualization by the computer program Vitran.
fig. 1 shows electroforegram of GSTP1 (A313G) gene restricts.
Hydrolytic cleavage of normal allele by restryctase was 
performed by one restriction site appearance 5'...
GTCTCN1↓ ...3', resulting molecular weight fragments for-
mation 328 and 104 b.p. (AA-genotype). When nucleotides
adenine replace to guanine second restriction site appeared,
resulting molecular weight fragments formation 222 and 104
b.p. (GG-genotype)
Examples 1, 4, 8 – GG-genotype, examples 2, 3, 6 –
AG-genotype, examples 5, 7, 9-11 –AA-genotype, example
12 – negative control, M – molecular weight marker.
The quality of DNA isolation and conditions for 
multiplexed PCR setting was controlled by fragment of the
albumin gene amplification with a molecular weight of 350
b.p. In case of separate fragment absence in the sample 
during the multiplexed polymerase chain reaction electro-
phoretic division, results for this sample were not considered.
Key words: nonalcoholic fatty liver disease, glutathione-S-
transferase gene, polymorphism
l'activité plus élevée du syndrome cytolytique chez les patients
observés. 
Mots clés: la stéatose non alcoolique hépatique, des gènes 
glutathion-S-transférase, polymorphisme
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Statistical processing of the data was performed by the
computer program PAST Version 2.05 [6]. To determine the
type of data distribution, comparing the arithmetic mean,
median and mode, and Wilcoxon-Shapiro test were used. To
determine the statistical differences between two indepen-
dent groups Mann-Whitney test was applied. Hardy-
Weinberg equilibrium was calculated by a chi-square test.
Odds-ratio was determined. P values < 0,05 were considered
statistically significant.
RESULTS AND DISCUSSION
A313G polymorphism of GSTP1 gene in 64 patients
with NAFLD and 20 healthy individuals (control group) was
studied. The distribution of genotypes of GSTP1 gene poly-
morphism in NAFLD patients is presented in table 2.
Among these patients AA genotype was diagnosed in 30
persons (46.9%), AG – 24 (37.5%), GG – 10 (15.6%); 
A-allele of GSTP1 gene was observed in 84 cases (65.6%)
among 128 selected alleles, G-allele – in 44 cases (34.4%)
respectively. 
In the group of healthy volunteers homozygous carriers of
Ala-allele were found 14 (70.0%), 5 persons (25.0%) from
this group were heterozygotes, 1 person (5.0%) – homozygous
carriers of G-allele. A-allele of GSTP1 gene was observed in
33 cases (82.5%) among 40 selected alleles, G-allele – in 7
cases (17.5%) respectively. Similar distribution of the GSTP1
polymorphic variants among healthy people of Bashkir 
population was obtained [1]. By OR calculation we found
that G-allele significantly more frequently in 2.47 times 
(OR=2,47, CI=1.01-6.03, p<0.05) occurred in NAFLD
patients compared with healthy individuals. Our data are 
consonant with the results of M. Hashemi et al., which
shows that G-allele of GSTP1 gene is a risk factor for
NAFLD formation in the Iranian population [7].
Association of biochemical blood parameters in NAFLD
patients with GSTP1 gene polymorphic variants are shown
in table 3. The analysis of possible differences in parameters
of synthesizing, detoxification, excretory liver functions and
activity of cytolytic and cholestatic syndromes between 
different polymorphic variants of A313G polymorphism
GSTP1 gene was performed. Total bilirubin level in blood of
patients with GG-genotype was by 19.7% (p=0.03) and
36.9% (p = 0.04) higher compared with AA-genotype and
AG-genotype carriers respectively. Presence of G-allele was
also associated with increased ALT activity, which was 
significantly higher in NAFLD patients AG- and GG-geno-
types carriers compared to patients with AA-genotype at
60.7% (p = 0.03) and 51.0% (p = 0.04) respectively. More-
over homozygotes by G-allele showed a tendency to increased
AST and GGT activities, but this was not confirmed statis-
tically. We have also detected some peculiarities in the 
carbohydrates metabolism in NAFLD patients depending on
polymorphic variants of GSTP1 gene. In particular, glucose
Table 1- Primer sequences, restriction enzyme and allele calling for GSTP1 SNPs
Gene (polymorphism) Primer sequences (5’-3’) Allele calling 
(size of fragments, b.p.)
GSTP1 (A313G) GTAGTTTGCCCAAGGTCAAG - forward 432 b.p.
AGCCACCTGAGGGGTAAG – reverse
Internal control of amplification GCCCTCTGCTAACAAGTCCTAC 350 b.p.
GCCCTAAAAAGAAAATCGCCAATC
Figure 1 - Electroforegram 
of GSTP1 gene amplified 
fragment distribution 
Table 2 - Distribution of GSTP1 gene polymorphism (A313G) in patients with nonalcoholic fatty liver disease and healthy individuals
GSTP1 Patients with NAFLD Healthy volunteers
gene genotype (n = 64) (n = 20)
Absolute quantity, n Percentage Absolute quantity, n Percentage
AA 30 46.9% 14 70.0%
AG 24 37.5% 5 25.0%
GG 10 15.6% 1 5.0%
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plasma level was the lowest in heterozygotes and the highest
in homozygotes by A-allele. Homozygotes by G-allele showed
intermediate concentration of glucose in blood. The mecha-
nisms of revealed dependence remain unclear, thus requiring
more investigations to explain this phenomenon. 
CONCLUSIONS
Frequency of G-allele of GSTP1 gene was by 2.47
times (OR = 2.47, CI = 1.01-6.03, p<0.05) higher in
NAFLD patients compared with healthy individuals in
Ukrainian population. Presence of G-allele was associated
with increased concentration of total bilirubin and higher
activity of cytolytic syndrome in NAFLD patients.  
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